135 related articles for article (PubMed ID: 27372109)
1. Omarigliptin for the treatment of type 2 diabetes.
Tan X
Endocrine; 2016 Oct; 54(1):24-31. PubMed ID: 27372109
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
Jain L; Chain ASY; Tatosian DA; Hing J; Passarell JA; Kauh EA; Lai E
Br J Clin Pharmacol; 2019 Dec; 85(12):2759-2771. PubMed ID: 31454094
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Goldenberg R; Gantz I; Andryuk PJ; O'Neill EA; Kaufman KD; Lai E; Wang YN; Suryawanshi S; Engel SS
Diabetes Obes Metab; 2017 Mar; 19(3):394-400. PubMed ID: 28093853
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.
Sheu WH; Gantz I; Chen M; Suryawanshi S; Mirza A; Goldstein BJ; Kaufman KD; Engel SS
Diabetes Care; 2015 Nov; 38(11):2106-14. PubMed ID: 26310692
[TBL] [Abstract][Full Text] [Related]
5. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Shankar RR; Inzucchi SE; Scarabello V; Gantz I; Kaufman KD; Lai E; Ceesay P; Suryawanshi S; Engel SS
Curr Med Res Opin; 2017 Oct; 33(10):1853-1860. PubMed ID: 28547998
[TBL] [Abstract][Full Text] [Related]
6. Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds.
Gantz I; Sokolova L; Jain L; Iredale C; O'Neill EA; Wei Z; Lam R; Suryawanshi S; Kaufman KD; Engel SS; Lai E
Clin Ther; 2017 Oct; 39(10):2024-2037. PubMed ID: 28923291
[TBL] [Abstract][Full Text] [Related]
7. Omarigliptin for the treatment of type 2 diabetes mellitus.
Evans PM; Bain SC
Expert Opin Pharmacother; 2016 Oct; 17(14):1947-52. PubMed ID: 27466703
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Addy C; Tatosian D; Glasgow XS; Gendrano IN; Kauh E; Martucci A; Johnson-Levonas AO; Selverian D; Matthews CZ; Gutierrez M; Wagner JA; Aubrey Stoch S
Clin Ther; 2016 Mar; 38(3):516-30. PubMed ID: 26869191
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.
Gantz I; Okamoto T; Ito Y; Okuyama K; O'Neill EA; Kaufman KD; Engel SS; Lai E;
Diabetes Obes Metab; 2017 Nov; 19(11):1602-1609. PubMed ID: 28449368
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
Wang X; Li X; Qie S; Zheng Y; Liu Y; Liu G
Medicine (Baltimore); 2018 Aug; 97(34):e11946. PubMed ID: 30142816
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Handelsman Y; Lauring B; Gantz I; Iredale C; O'Neill EA; Wei Z; Suryawanshi S; Kaufman KD; Engel SS; Lai E
Curr Med Res Opin; 2017 Oct; 33(10):1861-1868. PubMed ID: 28548024
[TBL] [Abstract][Full Text] [Related]
12. Omarigliptin: first global approval.
Burness CB
Drugs; 2015 Nov; 75(16):1947-52. PubMed ID: 26507988
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes.
Home P; Shankar RR; Gantz I; Iredale C; O'Neill EA; Jain L; Pong A; Suryawanshi S; Engel SS; Kaufman KD; Lai E
Diabetes Res Clin Pract; 2018 Apr; 138():253-261. PubMed ID: 29079379
[TBL] [Abstract][Full Text] [Related]
14. Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
Tsuchiya S; Friedman E; Addy C; Wakana A; Tatosian D; Matsumoto Y; Suzuki H; Kauh E
J Diabetes Investig; 2017 Jan; 8(1):84-92. PubMed ID: 27182005
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological action and clinical results of Omarigliptin (MARIZEV
Ito Y; Mori M; Matsumoto Y; Okamoto T
Nihon Yakurigaku Zasshi; 2017; 149(3):128-137. PubMed ID: 28260743
[No Abstract] [Full Text] [Related]
16. Pharmacokinetics and Pharmacodynamics of Omarigliptin, a Once-Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitor, After Single and Multiple Doses in Healthy Subjects.
Krishna R; Addy C; Tatosian D; Glasgow XS; Gendrano Iii IN; Robberechts M; Haazen W; de Hoon JN; Depré M; Martucci A; Peng JZ; Johnson-Levonas AO; Wagner JA; Stoch SA
J Clin Pharmacol; 2016 Dec; 56(12):1528-1537. PubMed ID: 27225334
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
Lee SH; Gantz I; Round E; Latham M; O'Neill EA; Ceesay P; Suryawanshi S; Kaufman KD; Engel SS; Lai E
BMC Endocr Disord; 2017 Nov; 17(1):70. PubMed ID: 29110647
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
Gantz I; Chen M; Suryawanshi S; Ntabadde C; Shah S; O'Neill EA; Engel SS; Kaufman KD; Lai E
Cardiovasc Diabetol; 2017 Sep; 16(1):112. PubMed ID: 28893244
[TBL] [Abstract][Full Text] [Related]
19. A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.
Chacra A; Gantz I; Mendizabal G; Durlach L; O'Neill EA; Zimmer Z; Suryawanshi S; Engel SS; Lai E
Int J Clin Pract; 2017 Jun; 71(6):. PubMed ID: 28449320
[TBL] [Abstract][Full Text] [Related]
20. Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study.
Ohara M; Nagaike H; Fujikawa T; Kohata Y; Ogawa M; Omachi T; Sasajima R; Chiba H; Ara T; Sugawara A; Hiromura M; Terasaki M; Mori Y; Fukui T; Hirano T; Yokoyama H; Yamagishi SI
Diabetes Res Clin Pract; 2021 Sep; 179():108999. PubMed ID: 34390762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
